# Maladaptive Trained Immunity Drives Persistent IL-6 Production and Enhanced TLR Responsiveness in Monocyte-Derived Macrophages from People Living with HIV

**Authors:** Larisa Dubrovsky, Tatiana Pushkarsky, Beda Brichacek, Ashley Bastin, Afsoon Roberts, Jose Lucar, Maria Elena Ruiz, Oleksandr Semeniuk, Marc Siegel, Dmitri Sviridov, Michael I. Bukrinsky

PMC · DOI: 10.3390/microorganisms14020355 · Microorganisms · 2026-02-03

## TL;DR

This study shows that people living with HIV have a faulty immune response that causes ongoing inflammation without protecting against the virus.

## Contribution

The study identifies maladaptive trained immunity in HIV patients, linking it to persistent inflammation without antiviral benefits.

## Key findings

- PLWH macrophages show heightened IL-6 production after TLR2 and TLR7 stimulation.
- IL-6 output correlates with HIV infection duration, suggesting cumulative immune reprogramming.
- Maladaptive trained immunity does not reduce HIV susceptibility in macrophages.

## Abstract

Trained immunity (TRIM) enhances innate immune responses through epigenetic and metabolic reprogramming but may become maladaptive, contributing to chronic inflammation. In people living with HIV (PLWH), maladaptive TRIM has been proposed but remains insufficiently characterized. We examined inflammatory cytokine production in monocyte-derived macrophages (MDMs) obtained from PLWH and age-matched individuals without HIV infection. Baseline cytokine output and responses to stimulation of Toll-like receptors (TLR) were measured. We further examined whether TRIM influenced susceptibility to HIV infection in MDMs derived from monocytes exposed to extracellular vesicles carrying the HIV-1 Nef protein (Nef EVs). Baseline IL-6 production did not differ between unstimulated MDMs from PLWH and uninfected controls. Although sex-associated differences were initially observed, these effects were no longer significant after adjustment for infection duration. IL-6 responses following TLR2 and TLR7 stimulation, but not TLR4 stimulation, were significantly amplified in PLWH-derived MDMs, consistent with a trained phenotype. Similar trends were observed in sex-stratified analyses but did not reach statistical significance. The magnitude of unstimulated IL-6 production positively correlated with duration of HIV infection, suggesting cumulative TRIM imprinting over time. Despite heightened inflammatory responsiveness, TRIM did not reduce susceptibility to HIV infection in Nef EV-exposed MDMs, indicating functional maladaptation rather than protective priming. These findings provide evidence of maladaptive TRIM in PLWH, characterized by preserved basal cytokine output but exaggerated inflammatory responses to innate immune stimulation without antiviral benefit. The association with infection duration supports progressive innate immune reprogramming as a contributor to HIV-associated inflammation. No statistically significant differences in trained immune responses were observed between male and female PLWH after accounting for duration of infection. Further studies are needed to define the mechanisms underlying this maladaptation and its clinical consequences.

## Linked entities

- **Proteins:** S100B (S100 calcium binding protein B)
- **Diseases:** HIV infection (MONDO:0005109)

## Full-text entities

- **Genes:** MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, ADA (adenosine deaminase) [NCBI Gene 100] {aka ADA1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, NRSN1 (neurensin 1) [NCBI Gene 140767] {aka VMP, p24}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PDCD6IP (programmed cell death 6 interacting protein) [NCBI Gene 10015] {aka AIP1, ALIX, DRIP4, HP95, MCPH29}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, CD14 (CD14 molecule) [NCBI Gene 929], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, TRAT1 (T cell receptor associated transmembrane adaptor 1) [NCBI Gene 50852] {aka HSPC062, TCRIM, TRIM, pp29/30}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Nef [NCBI Gene 156110], CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}
- **Diseases:** PLWH (MESH:C000719191), chronic (MESH:D002908), HIV (MESH:D015658), immune dysregulation (OMIM:614878), viral infections (MESH:D014777), cardiovascular disease (MESH:D002318), infected (MESH:D007239), autoimmune-like conditions (MESH:D001327), inflammatory training (MESH:D000095027), injury to (MESH:D014947), chronic inflammation (MESH:D007249)
- **Chemicals:** LPS (MESH:D008070), lipid (MESH:D008055), CO2 (MESH:D002245), L-Glutamine (MESH:D005973), R-848 (MESH:C402365), Pen (MESH:C058388), PBS (MESH:D007854), Mg2+ (-), DPBS (MESH:C012939)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Cell lines:** HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943229/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943229/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943229/full.md

---
Source: https://tomesphere.com/paper/PMC12943229